Related Experiment Video
Updated: Jan 24, 2026

Contrast Enhanced Vessel Imaging using MicroCT
Published on: January 27, 2011
How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
Albert T Roh1, Richard E Fan2, Geoffrey A Sonn3
1Department of Radiology, Stanford University, Stanford, CA.
Background:
Prostate imaging reporting and data system version 2 (PI-RADS v2) relegates dynamic contrast enhanced (DCE) imaging to a minor role. We sought to determine how often DCE is used in PI-RADS v2 scoring.
Materials And Methods:
We retrospectively reviewed data from 388 patients who underwent prostate magnetic resonance imaging and subsequent biopsy from January 2016 through December 2017. In accordance with PI-RADS v2, DCE was deemed necessary if a peripheral-zone lesion had a diffusion-weighted imaging score of 3, or if a transition-zone lesion had a T2 score of 3 and diffusion-weighted imaging experienced technical failure. Receiver operating characteristic curve analysis assessed the accuracy of prostate-specific antigen density (PSAD) at different threshold values for differentiating lesions that would be equivocal with noncontrast technique. Accuracy of PSAD was compared to DCE using McNemar's test.
Results:
Sixty-nine lesions in 62 patients (16%) required DCE for PI-RADS scoring. Biopsy of 10 (14%) of these lesions showed clinically significant cancer (Gleason score ≥7). In the subgroup of patients with equivocal lesions, those with clinically significant cancer had significantly higher PSADs than those with clinically insignificant lesions (means of 0.18 and 0.13 ng/mL/mL, respectively; P= 0.038). In this subgroup, there was no statistical difference in accuracy in determining clinically significant cancer between a PSAD threshold value of 0.13 and DCE (P= 0.25).
Conclusions:
Only 16% of our patients needed DCE to generate the PI-RADS version 2 score, raising the possibility of limiting the initial screening prostate MRI to a noncontrast exam. PSAD may also be used to further decrease the need for or to replace DCE altogether.
Insights
Dynamic contrast enhanced (DCE) imaging is infrequently needed for Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring. Prostate-specific antigen density (PSAD) may reduce or replace the need for DCE in prostate MRI.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) guidelines assign a limited role to dynamic contrast enhanced (DCE) imaging.
- This study investigated the actual utilization frequency of DCE in PI-RADS v2 scoring.
Purpose of the Study:
- To evaluate the necessity of DCE in PI-RADS v2 scoring for prostate MRI.
- To explore the potential of prostate-specific antigen density (PSAD) as an alternative to DCE.
Main Methods:
- Retrospective review of 388 patients undergoing prostate MRI and biopsy (January 2016 - December 2017).
- DCE was indicated based on specific PI-RADS v2 criteria for peripheral and transition zone lesions.
- Receiver operating characteristic curve analysis assessed PSAD accuracy for differentiating lesions, compared to DCE using McNemar's test.
Main Results:
- Only 16% of patients (62/388) required DCE for PI-RADS v2 scoring.
- Clinically significant cancer (Gleason score ≥7) was found in 14% (10/69) of lesions requiring DCE.
- In equivocal lesions, PSAD thresholds showed comparable accuracy to DCE in identifying significant cancer.
Conclusions:
- The limited use of DCE (16%) suggests that initial screening prostate MRI could potentially exclude contrast agents.
- Prostate-specific antigen density (PSAD) demonstrates potential to reduce or replace the need for DCE in PI-RADS v2 assessments.
Related Concept Videos
PI Controller: Design
The Buckingham Pi Theorem
Determination of Pi Terms
The theorem indicates that the...
Self-Evaluation: Self-Enhancement and Self-Verification
Introduction to z Scores
z scores...
Introduction to z Scores
z scores...

